Bilateral renal artery stenosis in a patient with chronic myeloid leukemia treated with nilotinib  by Kristensen, Tilde et al.
Leukemia Research Reports 1 (2012) 1–3Contents lists available at SciVerse ScienceDirectLeukemia Research Reports2213-04
http://d
n Corr
Hospita
fax: þ4
E-mjournal homepage: www.elsevier.com/locate/lrrCase ReportBilateral renal artery stenosis in a patient with chronic myeloid leukemia
treated with nilotinibTilde Kristensen a,n, Else Randers a, Jesper Stentoft b
a Department of Internal Medicine, Viborg Regional Hospital, Viborg, Denmark
b Department of Hematology, University Hospital Aarhus, Aarhus, Denmarka r t i c l e i n f o
Article history:
Received 25 July 2012
Received in revised form
9 September 2012
Accepted 17 September 2012
Available online 10 November 2012
Keywords:
Renal artery stenosis
Leukemia
Tyrosine kinase inhibitor
Renovascular hypertension89 & 2012 Elsevier Ltd.
x.doi.org/10.1016/j.lrr.2012.09.002
espondence to: Department of Internal Medi
l, Heibergs Alle’ 4, 8800 Viborg, Denmark. Te
5 7844 7075.
ail address: Tilde.Kristensen@Viborg.RM.dk (T
Open access under CC Ba b s t r a c t
Previously authors have recently described an association between nilotinib therapy for chronic
myeloid leukemia (CML) and severe peripheral artery disease, coronary artery disease and sudden
death. We present a case report of a male patient with CML who received nilotinib therapy. He
developed bilateral renal artery stenosis and renovascular hypertension. He had no history of
hypertension, cardiovascular disease, or diabetes, and he was a nonsmoker. Together, these observa-
tions indicated that obtaining further understanding of the effects is necessary and that extreme
caution is warranted when considering second-generation tyrosine kinase inhibitors for ﬁrst-line
therapy in CML.
& 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.We present a case report of a patient with chronic myeloid
leukemia (CML) who developed bilateral renal artery stenosis
during tyrosine kinase inhibitor (TKI) therapy. Only a few reports
associate TKIs with acute renal failure,1,2 and renovascular
hypertension has not been previously described. Reports on
peripheral artery occlusive disease occurring during nilotinib
therapy have recently been published.3,4
A 58-yr-old, nonsmoking, nondiabetic male patient with no
history of cardiovascular disease or hypertension was diagnosed
with CML in 2001. He was secondarily refractory to imatinib as a
result of ABL mutations and developed a myeloid blast crisis in
May 2006. Induction therapy with dasatinib was successful,
leading to a major molecular remission, but in 2008, the patient
had recurrent pleural effusions. The therapy was switched to
400 mg nilotinib twice daily in April 2008.
The patient was hospitalized in August 2009 after a 6-month
period of tinnitus, dizziness, headache, and vision disturbance.
At the time of admission, his blood pressure was 260/140 mmHg.
An electrocardiogram (ECG) showed no signs of left ventricular
hypertrophy, and an x-ray of the chest was normal. Ophthalmo-
scopy did not show hypertensive retinopathy. An echocardiogra-
phy did not indicate any signs of left ventricular hypertrophy.
A urinary dipstick was negative for protein.cine, Viborg Regional
l.: þ45 7844 7000;
. Kristensen).
Y-NC-ND license.Examination of the blood tests showed slightly decreased
glomerular function with creatinine increasing from 104 mmol/l
to 160 mmol/l (reference range 60–105 mmol/l) in the ﬁrst 5 days
following admission. The patient started treatment with alpha
and beta inhibitors, angiotensin-converting enzyme (ACE) inhibi-
tor and calcium antagonists.
During hospitalization, the patient experienced dysarthria,
hemianopsia and right-sided facialis nerve paresis. His blood
pressure was 185/100 mmHg. A computed tomography (CT) scan
of the cerebrum showed an old infarction in the caudate nucleus
and the internal capsula but no recent bleedings or infarctions.
The patient started treatment with aspirin, dipyridamole and
simvastatin.
Captopril renography showed that the relative uptakes in the
right and left kidneys were 35% and 65%, respectively, and
showed delayed excretion from the right kidney.
The antihypertensive treatment was optimized with diuretics. An
ultrasound of the kidney was normal except for thickening of the
bladder wall due to a known hypertrophy of the prostate gland.
A renography was performed after 2 weeks without ACE
inhibitor treatment. The renography demonstrated that the right
kidney had a low relative uptake, accounting for only 11% of the
renal function. CT angiography showed bilateral renal artery
stenosis, which was more severe on the right side. No athero-
sclerosis was found in the renal artery or in the aorta.
The patient was treated with endovascular stents in both renal
arteries. There were no complications (Fig. 1).
The patient has been followed as an out-patient, and the most
recent blood pressure measurement was 140/50 mmHg (May
Fig. 1. CT angiography with contrast. (a) Renal artery stenosis on the right side. (b) Renal artery stenosis on the left side. (c) After treatment with bilateral percutan
transluminal renal angioplasty.
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creatinine level was 119 mmol/l. Nilotinib has been continued at
the same dosage, and the patient remains stable in complete
molecular remission.
Chronic myeloid leukemia is a myeloproliferative disorder
characterized by the occurrence of the fusion gene BCR-ABL
located on the derivative chromosome 22 (Philadelphia chromo-
some), which results from a translocation between chromosome
9 and 22. Tyrosine kinase inhibitors (TKIs) targeted against the
BCR-ABL kinase have revolutionized CML treatment by reducing
the number of patients progressing to an accelerated phase or a
blast crisis.5 TKIs are generally well tolerated.
The most frequent nonhematological side effects of TKIs are
ﬂuid retention, rash, pruritus, nausea, fatigue and headache.
Biochemically, the elevation of pancreatic enzymes, fasting
glucose, and cholesterol levels has been reported in some
patients. Congestive heart failure and left ventricular dysfunction
have been observed.6
Among unselected hypertension patients, the frequency of
renal artery stenosis is 0.5%, but the frequency is as high as
10%–20% in patients with severe hypertension.7
Renal artery stenosis is common in elderly patients with
general atherosclerosis. Renal artery stenosis due to ﬁbromuscu-
lar dysplasia in the renal artery is most commonly observed in
younger women. Renovascular hypertension can be treated
medically or by surgery and endovascular procedures.
In our case, the patient showed no signs of long-lasting
hypertension, and there were no signs of signiﬁcant atherosclerosis.
We ﬁnd that the renal artery stenosis was most likely caused by
nilotinib.
There are only a few reports on renal dysfunction in patients
treated with TKIs. Less than 1% of patients with normal baseline
renal function developed renal failure.1 The renal excretion of
TKIs is low. Two different possible mechanisms responsible for
TKI-associated renal failure have been suggested: tumor lysis
syndrome and toxic tubular damage caused by the drug. Mouse
and rat models of accelerated diabetic nephropathy, renal ﬁbro-
genesis, autoimmune glomerulonephritis or lupus nephritis have
associated TKI therapy with renal injury. These studies suggested
that interstitial ﬁbrosis is a common mechanism for renal injury
and that signaling pathways mediated by tyrosine kinases play a
role in the pathogenesis of this injury.2 To our knowledge, there
are no reports on nilotinib leading to renal artery stenosis,
but recent reports of peripheral and coronary artery occlusive
disease3,4 have drawn attention to this potentially serious side
effect. Long-term safety data for nilotinib are not available yet.
It has been described that it increases the fasting glucose level
and thereby provokes diabetes mellitus.8 Recent data suggest that
nilotinib bind to key kinase targets such as discoidin domain
receptor 1 (DDR1). This receptor has been implicated in plaque
formation in atherosclerosis.9 Nilotinib is a blocker of the receptor
kinase KIT which is found to be a major regulator of mast cellswhich regulates molecules as histamine and heparine.10 This
could also contribute to depressed vascular repair system and
thereby predispose to thromboembolic and arterostenotic events.
Maybe multiple mechanisms are responsible for these vascular
events.
The frequency of nilotinib-induced renal artery stenosis is
uncertain. In the present case, it is tempting to hypothesize that
the occlusive renal artery disease has the same pathogenesis as
the peripheral artery occlusive disease. The patient was in a deep
molecular response at the onset of the hypertension, and tumor
lysis syndrome was not a consideration.
While disorders related to atherosclerotic and ﬁbromuscular
diseases are the most common causes of renal artery stenosis,
it should be recognized that any structural disorder reducing renal
perfusion to kidney tissue is capable of producing endovascular
hypertension.
TKIs are a highly targeted class of therapeutics for CML. It is
becoming increasingly clear that off-target side effects may be
clinically relevant. Further understanding of the effects is neces-
sary, and extreme caution is warranted when considering second-
generation TKIs for ﬁrst-line therapy in CML.Contribution
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